The FDA issued 50+ warning letters to compounders and telehealth distributors during the GLP-1 boom.
During 2025 the FDA issued more than 50 warning letters to compounders and telehealth companies, and flagged misleading marketing that implied compounded products were equivalent to the branded drugs. Ask any provider whether it has received a warning letter.
| What to know |
|---|
| The FDA issued 50+ warning letters to compounders and telehealth distributors during the GLP-1 boom. |
| During 2025 the FDA issued more than 50 warning letters to compounders and telehealth companies, and flagged misleading marketing that implied compounded products were equivalent to the branded drugs. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.